{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T20:33:09Z","timestamp":1769632389416,"version":"3.49.0"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[1982,1,1]],"date-time":"1982-01-01T00:00:00Z","timestamp":378691200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[1982]]},"DOI":"10.1007\/bf00542329","type":"journal-article","created":{"date-parts":[[2004,11,18]],"date-time":"2004-11-18T12:53:34Z","timestamp":1100782414000},"page":"417-419","source":"Crossref","is-referenced-by-count":45,"title":["Transplacental passage and breast milk concentrations of hydralazine"],"prefix":"10.1007","volume":"21","author":[{"given":"H.","family":"Liedholm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"W\ufffdhlin-Boll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Ingemarsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Melander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","volume-title":"Hypertension in pregnancy. Concepts and Management","author":"NF Gant","year":"1980","unstructured":"Gant NF, Worley RJ (1980) Hypertension in pregnancy. Concepts and Management. Appleton, New York"},{"key":"CR2","first-page":"116","volume":"5","author":"SB Zak","year":"1977","unstructured":"Zak SB, Lucas G, Gilleran TG (1977) Plasma levels of real and ?apparent? hydralazine in man and rat. Drug Metab Dispos 5: 116?121","journal-title":"Drug Metab Dispos"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/jps.2600670833","volume":"67","author":"PA Reece","year":"1978","unstructured":"Reece PA, Stanley PE, Zacest R (1978) Interference in assays for hydralazine in humans by a major plasma metabolite, hydralazine pyruvic acid hydrazone. J Pharm Sci 67: 1150?1153","journal-title":"J Pharm Sci"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0021-9673(00)89019-6","volume":"115","author":"DB Jack","year":"1975","unstructured":"Jack DB, Brechb\u00fchler S, Degen PH, Zbinden P, Riess W (1975) The determination of hydralazine in plasma by gas liquid chromatography. J Chromatogr 115: 87?92","journal-title":"J Chromatogr"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00542329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00542329\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00542329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T18:34:20Z","timestamp":1554402860000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00542329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1982]]},"references-count":4,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1982]]}},"alternative-id":["BF00542329"],"URL":"https:\/\/doi.org\/10.1007\/bf00542329","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[1982]]}}}